Anasayfa » What Is Kidney Cancer?
Renal pelvis cancer (UCC) is a type of cancer that starts in the center of the kidney where the urine collects and then drains into the ureter or bladder. Urothelial cells line the inside of the renal pelvis, ureters, bladder, and urethra. Urothelial cells are also found in the kidney; they originate in the fetus, and as the fetus grows, normal renal cells grow around the original urothelial cells. The cancer forms in one of these two types of cells.
The vast majority of urothelial cell carcinoma of the renal pelvis start off as papillary tumors that form along the lining of the renal pelvis. Occasionally, flat or sessile tumors form which have a lower risk of becoming invasive. These sessile tumors are another possible type of superficial UCC of the renal pelvis. Other rarer types of UCC can occur in the central portion of the kidney. The incidence of urothelial cancer of the kidney appears to increase with age. UCC of the renal pelvis has been diagnosed and treated in patients who are as young as 13 years old.
Kidney cancer is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis. These names reflect the type of cell from which they start. Renal cell carcinoma begins in the lining of the renal tubules in the kidney that filter the blood and produce urine.
Renal tubular cells have small tubes called tubules through which the urine drains into the bladder. Renal cell carcinoma is by far the most common type of kidney cancer in adults. A mass in the kidney is not necessarily renal cell carcinoma. There are non-cancerous masses found in the kidney that are benign. These tumors do not spread throughout the body as renal cell carcinoma does and the cells do not invade other tissues within the body.
Because of their specific pharmacokinetics, the chemotherapy agents for kidney cancer are generally well tolerated by the majority of the oncological patients. Using the new oral kidney cancer chemotherapeutic agents such as Sunitinib, Sorafenib, Temsirolimus, studies have shown that anti-tumor efficacy is not related to the patient’s chronic renal failure. Blood dialysis has no clear indications in renal cancer and would be potentially effective if it might prove its anti-tumor activity. This is the case with Interleukin-2.
The side effects or, better said, toxic effects observed as a result of the kidney cancer therapy are variable ranging from patient to patient. The effects vary directly proportional to the used chemotherapy dose, the time period of exposure to the ascertained substances, and the general state of health of the patient, and the previous treatments for instance radiotherapy, immunotherapy. The toxic effects are known only as a result of the employed substance’s inhibition procedure on conjunct body organs. These phenomena limit the use of a few chemotherapy agents or better said, it is treated with caution, especially in patients with diminished renal function.
At about 50% of the patients, kidney cancer is identified at the first consultation of the patient to a urologist, through renal tumors (without symptoms). Specific to renal tumors are: hematuria, the presence of blood in the urine, backache, hemoptysis, pollakiuria (frequent emission of urine), abdominal mass, erythrocythemia (too many red blood cells in the blood). Other general symptoms can be: asthenia (feeling tired); perspiration especially during the night; dysplasia; severe weight loss.